Glasgow, Scotland, 29 November 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem of antibiotic resistance, will be attending BIO-Europe 2015. The Company will be represented by Dr Miroslav Ravic, CEO and Raymond Spencer, CFO.
MGB Biopharma, is a clinical stage company developing a truly novel class of anti-infectives. Its lead candidate, MGB-BP-3, is an antibacterial which is active against a broad range of important multi-resistant Gram-positive pathogens. The Company has developed an oral formulation of MGB-BP-3 for the treatment of Clostridium difficile, currently in Phase I. An intravenous formulation targeting the treatment of a range of systemic hospital acquired Gram-positive infections is in late-stage preclinical development, and a topical formulation for the treatment of serious skin infections has successfully completed a feasibility assessment.
Dr Miroslav Ravic, CEO MGB Biopharma said, “We are pleased to be attending BIO-Europe and are looking forward to meeting a range of industry participants to outline the significant potential of the oral formulation of our lead antibacterial MGB-BP-3 for the treatment of Clostridium difficile infections, and our broader MGB anti-infectives platform.”
BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies.
Help employers find you! Check out all the jobs and post your resume.
